BioGen’s “Aduhelm” is a monthly injection intended to slow cognitive decline in patients with early stages of the disease. The FDA granted the drug approval as a new clinical trial begins.
2025-11-01
A nationwide recall affects more than 500,000 bottles of a common blood pressure drug after ...
The FDA has now approved a new drug, the hormone-free medication Lynkuet, that is used ...